OCD AND ANXIETY
As people research options for mental health or addiction treatment, they ultimately want to know one thing: does your treatment work?
“It’s a fair and important question to ask, because those who come to Rogers are making a significant investment of time and resources, not to mention trusting their future to us,” comments Brad Riemann, PhD, chief clinical officer.
For more than 20 years, Rogers has been working to be able to answer the question in the most scientifically reliable way. Having refined the approach over time, Rogers conducts outcomes studies each year by analyzing approximately 600,000 assessments that patients take when they start treatment, at various points along the way, at discharge, and for many programs – 12 months later. These self-reported answers to the valid voluntary questionnaires allow us to see improvement in quality of life, depressive symptoms, obsessions and compulsions, or other indications of the patient’s mental health.
Examples of the questionnaires used for adults include:
Data from the outcomes studies are useful on many levels, starting with individual patients and extending across the industry:
“It’s gratifying to know that our treatments work, and these outcome studies allow us to quantify that our patients are getting better throughout treatment. But we also want to confirm that the new tools and skills they leave with will help them over the long haul,” explains Jerry Halverson, MD, chief medical officer.
That’s why Rogers does follow up assessments for a growing number of programs. Eventually, Rogers plans to assess all patients a year after their Rogers treatment to be certain that their improvements are sustained.
With the implementation of our electronic health record in recent years, Rogers has an opportunity to collect and analyze a growing pool of data.
Brian Kay, executive director of continuous improvement, says, “Ultimately, this allows us to better understand and demonstrate the quality of care being delivered across our system. The most exciting part is being able to use statistical analysis to gain insights into which factors contribute to the best outcomes for our patients.”
“Our comprehensive approach to measurement-based care makes Rogers quite unique among mental health providers, and it also helps us to achieve the Quadruple Aim by assuring high quality care, comments. Dr. Halverson.
Rogers measures outcomes for each residential and outpatient program for adults and children and adolescents, and results are available at rogersbh.org under Treatment Outcomes. Referring providers may be interested in greater detail on the statistical analysis, which is available at rogersbh.org/clinicaloutcomes.
A cost-benefit analysis for OCD treatment conducted by Dr. Brad Riemann, Brian Kay, and two professors has been published in the Journal of Clinical Psychiatry. The study compared the outcomes and costs of seven empirically-based treatment strategies including:
The data analyzed included patient-reported outcome measures at admission, discharge, and one year after care as well as total charges for the care provided.
Results showed that the treatment with the highest benefit (best clinical outcomes and most cost effective) was the option of PHP stepping down to IOP. Of the seven treatment strategies analyzed, four used data from Rogers programs. The results validated that patients benefit from the outpatient continuum of care that Rogers offers.
“This study provides us with some very important findings. Specifically, someone following a continuum of care from partial hospitalization to intensive outpatient not only does better in the short run but also in the long run over the course of a lifespan when compared to other powerful treatments. The study also produced evidence that following this continuum provides significant health care cost savings,” comments Dr. Brad Riemann, PhD, chief clinical officer and study co-author.
Share this article:
Have you or a loved one spent time at Rogers? We’d like to hear about your experience with us. Share your story here.